Larry D Anderson Jr

List of Publications by Year
in descending order

64	2,864	430874 18	189892 50
papers	citations	h-index	g-index

65	65	65	2307
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomideâ€pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. European Journal of Haematology, 2022, 108, 73-83.	2.2	8
2	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	1.2	9
3	Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncology, 2022, 18, 277-289.	2.4	20
4	Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis. Circulation, 2022, 145, 18-20.	1.6	41
5	More key players in the game for myeloma prognosis and therapy. British Journal of Haematology, 2022, , .	2.5	1
6	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer Journal, 2022, 12, 63.	6.2	5
7	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995.	5.2	5
8	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine, 2022, 387, 132-147.	27.0	173
9	Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.. Journal of Clinical Oncology, 2022, 40, 8011-8011.	1.6	4
10	Lenalidomide, bortezomib, and dexamethasone (RVd) Â± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.. Journal of Clinical Oncology, 2022, 40, LBA4-LBA4.	1.6	3
11	Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, 546-559.	1.2	16
12	The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement. Leukemia Research, 2021, 100, 106480.	0.8	5
13	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia, 2021, 35, 1722-1731.	7.2	35
14	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2021, 384, 705-716.	27.0	1,129
15	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 59.	17.0	11
16	Effect of age and frailty on the efficacy and tolerability of onceâ€weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	4.1	16
17	Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. Journal of Clinical Oncology, 2021, 39, 8036-8036.	1.6	3
18	Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.. Journal of Clinical Oncology, 2021, 39, 8016-8016.	1.6	38

#	Article	IF	Citations
19	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer Journal, 2021, 11, 116.	6.2	44
20	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. American Journal of Hematology, 2021, 96, E383-E386.	4.1	7
21	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American Journal of Hematology, 2021, 96, 1120-1130.	4.1	15
22	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. Blood, 2021, 138, 2852-2852.	1.4	7
23	Ascorbate Deficiency Is Associated with Severity of Cytokine Release Syndrome Following Therapy with Chimeric Antigen Receptor T-Cells. Blood, 2021, 138, 4801-4801.	1.4	0
24	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. Blood, 2021, 138, 79-79.	1.4	20
25	Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin. Blood, 2021, 138, 2723-2723.	1.4	3
26	Evaluating the Impact of Therapy Related Healthcare Team Burden on Selection of Novel Therapies for Chronic Lymphocytic Leukemia and Lymphoid Malignancies. Blood, 2021, 138, 4015-4015.	1.4	0
27	COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies. Blood, 2021, 138, 4134-4134.	1.4	2
28	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). Blood, 2021, 138, 1634-1634.	1.4	1
29	Clinical and Molecular Characteristics Associated with Vitamin C Deficiency in Myeloid Malignancies; Real World Data from a Prospective Cohort. Blood, 2021, 138, 1217-1217.	1.4	1
30	Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphomaâ€"A Unique Entity. American Journal of Clinical Pathology, 2020, 154, 816-827.	0.7	12
31	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	13.7	188
32	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 2020, 136, 936-945.	1.4	436
33	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological Oncology, 2020, 38, 353-362.	1.7	14
34	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Blood, 2020, 136, 16-17.	1.4	18
35	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. Blood, 2020, 136, 45-46.	1.4	19
36	Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study. Blood, 2020, 136, 35-36.	1.4	3

#	Article	IF	Citations
37	Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study. Blood, 2020, 136, 17-18.	1.4	3
38	Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study. Blood, 2020, 136, 50-52.	1.4	1
39	Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2020, 136, 28-29.	1.4	42
40	KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.. Journal of Clinical Oncology, 2020, 38, 8525-8525.	1.6	12
41	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. Blood, 2020, 136, 48-50.	1.4	0
42	Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e32-e33.	0.4	0
43	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. Blood, 2019, 134, 691-691.	1.4	37
44	A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy. Blood, 2019, 134, 3191-3191.	1.4	2
45	Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma. BMJ Case Reports, 2019, 12, e229312.	0.5	4
46	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2588-2594.	1.3	22
47	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology, 2018, 180, 821-830.	2.5	32
48	Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory WaldenstrÃ¶m macroglobulinemia: evidence for a graft- versus -lymphoma effect. Haematologica, 2018, 103, e252-e255.	3.5	2
49	Targeting B-cell maturation antigen with GSK2857916 antibodyâ€“drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncology, The, 2018, 19, 1641-1653.	10.7	193
50	Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma. Journal of Clinical Oncology, 2017, 35, 580-582.	1.6	6
51	Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies. , 2016, , .		1
52	First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. Blood, 2016, 128, 1148-1148.	1.4	23
53	Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. Blood, 2015, 126, 377-377.	1.4	6
54	Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM). Blood, 2015, 126, 728-728.	1.4	9

#	Article	IF	Citations
55	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. Blood, 2014, 124, 31-31.	1.4	11
56	A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aî²42 DNA vaccine for Alzheimer disease. Journal of Neuroimmunology, 2013, 254, 63-68.	2.3	29
57	DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimerâ€™s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation. Cellular and Molecular Neurobiology, 2011, 31, 867-74.	3.3	47
58	Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunology, Immunotherapy, 2011, 60, 985-997.	4.2	34
59	Successful Treatment of Relapsed and Refractory Extramedullary Acute Promyelocytic Leukemia With Tamibarotene. Journal of Clinical Oncology, 2011, 29, e534-e536.	1.6	16
60	Adoptive T-cell therapy for B-cell malignancies. Expert Review of Hematology, 2009, 2, 517-532.	2.2	7
61	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstromâ€™s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.. Blood, 2006, 108, 3034-3034.	1.4	4
62	Esophago-respiratory fistula. Gastrointestinal Endoscopy, 2003, 58, 255.	1.0	1
63	BONE MARROW TRANSPLANT CONDITIONING INTENSIFIED WITH LIPOSOMAL CLODRONATE TO ELIMINATE RESIDUAL HOST ANTIGEN PRESENTING CELLS FAILS TO AMELIORATE GVHD AND INCREASES PERI-BMT MORTALITY1. Transplantation, 2001, 71, 611-618.	1.0	8
64	HER-2/ neu peptide specificity in the recognition of HLA-A2 by natural killer cells. Cancer Immunology, Immunotherapy, 1999, 48, 401-410.	4.2	0